Title : Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.

Pub. Date : 2003 Apr 15

PMID : 12673719






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 SU5416 is a small-molecule RTK inhibitor (RTKI) that targets VEGFR-2, c-kit, and fms-related tyrosine kinase Flk2. Semaxinib fms related receptor tyrosine kinase 3 Homo sapiens